366 related articles for article (PubMed ID: 26817673)
1. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Gallia F; Balducci C; Nobile-Orazio E
J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; van den Berg LH; Vermeulen M; Brusse E; Cats EA; van der Kooi AJ; Notermans NC; van der Pol WL; van Schaik IN; van Nes SI; Hop WC; van Doorn PA
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1374-9. PubMed ID: 20587484
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.
Lucke IM; Adrichem ME; Wieske L; van der Kooi AJ; Verhamme C; van Schaik IN; Eftimov F
J Neurol Sci; 2019 Feb; 397():141-145. PubMed ID: 30623818
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
Racosta JM; Sposato LA; Kimpinski K
Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
[TBL] [Abstract][Full Text] [Related]
5. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
6. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
[TBL] [Abstract][Full Text] [Related]
7. The role of IVIg in autoimmune neuropathies: the latest evidence.
Hughes R
J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
[TBL] [Abstract][Full Text] [Related]
8. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic immune-mediated neuropathies: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and the Lewis-Sumner syndrome.
Sederholm BH
Semin Neurol; 2010 Sep; 30(4):443-56. PubMed ID: 20941678
[TBL] [Abstract][Full Text] [Related]
10. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.
Sala TP; Crave JC; Duracinsky M; Lepira Bompeka F; Tadmouri A; Chassany O; Cherin P
Autoimmun Rev; 2018 Sep; 17(9):873-881. PubMed ID: 30005853
[TBL] [Abstract][Full Text] [Related]
13. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England.
Mahdi-Rogers M; McCrone P; Hughes RA
Eur J Neurol; 2014; 21(1):34-9. PubMed ID: 23930744
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
Adrichem ME; Eftimov F; van Schaik IN
J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
[TBL] [Abstract][Full Text] [Related]
15. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Brannagan TH
Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
17. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
[TBL] [Abstract][Full Text] [Related]
18. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
Hughes RA
Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update.
Nobile-Orazio E; Gallia F; Tuccillo F; Terenghi F
Curr Opin Neurol; 2010 Oct; 23(5):519-23. PubMed ID: 20689427
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
